Under-served groups remain underserved as eligibility criteria routinely exclude them from breast cancer trials

被引:9
作者
Moloney, Carolyn [1 ]
Shiely, Frances [1 ,2 ,3 ,4 ]
机构
[1] Univ Coll, TRAMS Trials Res & Methodol Unit, HRB Clinical Research Facility,, Cork, Ireland
[2] Univ Coll, Sch Publ Hlth, Cork, Ireland
[3] Univ Coll Cork, HRB Clin Res Facil, TRAMS Trials Res & Methodol Unit, Coll Rd, Cork, Ireland
[4] Univ Coll Cork, Sch Publ Hlth, Coll Rd, Cork, Ireland
关键词
Breast cancer; Randomized trials; Underserved groups; Trial methodology; Inclusivity; PHASE-III TRIAL; DOUBLE-BLIND; OPEN-LABEL; CAPECITABINE MONOTHERAPY; ADJUVANT TREATMENT; 1ST-LINE THERAPY; CLINICAL-TRIALS; DOSE-DENSE; CHEMOTHERAPY; WOMEN;
D O I
10.1016/j.jclinepi.2022.03.011
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: Under-served groups are populations unrepresented or disengaged from medical research or services despite a disproportionately high healthcare burden. Under-served groups may be directly (age, pregnancy as examples) or indirectly excluded (provision of written information in one language only as an example) from trial enrollment by strict eligibility exclusions. The purpose of our study was to assess eligibility criteria in published phase III breast cancer clinical trials to determine whether they excluded underserved groups either directly or indirectly. Study Design and Setting: Medline was searched for phase III randomized controlled trials evaluating interventional drugs for breast cancer in high-impact journals published between January 1st, 2010 and December 31st, 2020. A total of 5133 eligible trials were returned, and 40 were selected, by simple randomization, for inclusion. Results: All 40 trials had multiple exclusions that affected the recruitment of underserved groups. Clinical or scientific rationale for the recorded inclusion and exclusion criteria was underreported in 39 of 40 trials. Conclusion: Clinical trial eligibility criteria exclude underserved groups from breast cancer trials. Trialists should provide a justification for each eligibility criterion, and funders, reviewers, ethics committees, and others should demand one. Without this, underserved groups will remain just that: underserved. (C) 2022 The Author(s). Published by Elsevier Inc.
引用
收藏
页码:132 / 141
页数:10
相关论文
共 77 条
[1]  
Abrey LE., 2011, Clin Investig, V1, P1065
[2]   Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].
Andre, Fabrice ;
Ciruelos, Eva ;
Rubovszky, Gabor ;
Campone, Mario ;
Loibl, Sibylle ;
Rugo, Hope S. ;
Iwata, Hiroji ;
Conte, Pierfranco ;
Mayer, Ingrid A. ;
Kaufman, Bella ;
Yamashita, Toshinari ;
Lu, Yen-Shen ;
Inoue, Kenichi ;
Takahashi, Masato ;
Papai, Zsuzsanna ;
Longin, Anne-Sophie ;
Mills, David ;
Wilke, Celine ;
Hirawat, Samit ;
Juric, Dejan .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940
[3]   Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial [J].
Andre, Fabrice ;
O'Regan, Ruth ;
Ozguroglu, Mustafa ;
Toi, Masakazu ;
Xu, Binghe ;
Jerusalem, Guy ;
Masuda, Norikazu ;
Wilks, Sharon ;
Arena, Francis ;
Isaacs, Claudine ;
Yap, Yoon-Sim ;
Papai, Zsuzsanna ;
Lang, Istvan ;
Armstrong, Anne ;
Lerzo, Guillermo ;
White, Michelle ;
Shen, Kunwei ;
Litton, Jennifer ;
Chen, David ;
Zhang, Yufen ;
Ali, Shyanne ;
Taran, Tetiana ;
Gianni, Luca .
LANCET ONCOLOGY, 2014, 15 (06) :580-591
[4]   Striving for Diversity in Research Studies [J].
不详 .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) :1429-1431
[5]   World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects [J].
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (20) :2191-2194
[6]  
[Anonymous], 2006, NIH PUBL
[7]   Factors associated with participation in breast cancer treatment clinical trials [J].
Avis, NE ;
Smith, KW ;
Link, CL ;
Hortobagyi, GN ;
Rivera, E .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) :1860-1867
[8]  
Bartlett C, 2005, HEALTH TECHNOL ASSES, V9, P1
[9]   Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Baselga, Jose ;
Im, Seock-Ah ;
Iwata, Hiroji ;
Cortes, Javier ;
De laurentiis, Michele ;
Jiang, Zefei ;
Arteaga, Carlos L. ;
Jonat, Walter ;
Clemons, Mark ;
Ito, Yoshinori ;
Awada, Ahmad ;
Chia, Stephen ;
Jagiello-Gruszfeld, Agnieszka ;
Pistilli, Barbara ;
Tseng, Ling-Ming ;
Hurvitz, Sara ;
Masuda, Norikazu ;
Takahashi, Masato ;
Vuylsteke, Peter ;
Hachemi, Soulef ;
Dharan, Bharani ;
Di Tomaso, Emmanuelle ;
Urban, Patrick ;
Massacesi, Cristian ;
Campone, Mario .
LANCET ONCOLOGY, 2017, 18 (07) :904-916
[10]   Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].
Baselga, Jose ;
Bradbury, Ian ;
Eidtmann, Holger ;
Di Cosimo, Serena ;
de Azambuja, Evandro ;
Aura, Claudia ;
Gomez, Henry ;
Dinh, Phuong ;
Fauria, Karine ;
Van Dooren, Veerle ;
Aktan, Gursel ;
Goldhirsch, Aron ;
Chang, Tsai-Wang ;
Horvath, Zsolt ;
Coccia-Portugal, Maria ;
Domont, Julien ;
Tseng, Ling-Min ;
Kunz, Georg ;
Sohn, Joo Hyuk ;
Semiglazov, Vladimir ;
Lerzo, Guillermo ;
Palacova, Marketa ;
Probachai, Volodymyr ;
Pusztai, Lajos ;
Untch, Michael ;
Gelber, Richard D. ;
Piccart-Gebhart, Martine .
LANCET, 2012, 379 (9816) :633-640